Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

International Stem Cell Corporation (ISCO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
At close: 02:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.5000
Open0.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4000 - 0.5000
52 Week Range0.3000 - 0.8000
Volume915
Avg. Volume3,101
Market Cap4.002M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0390
Earnings DateJun 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ISCO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • INTERNATIONAL STEM CELL CORPORA
    Analyst Report: Thermo Fisher Scientific Inc.Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).
    Rating
    Fair Value
    Economic Moat
    24 days agoMorningstar
View more
  • ACCESSWIRE

    International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

    SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022.

  • ACCESSWIRE

    International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results

    SAN DIEGO, CA / ACCESSWIRE / March 30, 2022 / International Stem Cell Corporation (OTCQX:ISCO) (www.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2021.

  • GlobeNewswire

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the “Board”). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier ha

Advertisement
Advertisement